Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ™ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping PRISTIQ to wholesalers beginning in the second quarter of 2008.
Popularity: unranked [?]
Related posts:
- Wyeth’s Pristiq, A New Treatment For Major Depressive Disorder
- New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms Of Major Depressive Disorder Versus Placebo
- New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms Of Major Depressive Disorder Versus Placebo
- Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
- Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
Comments
No Responses to “FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder”